Monitoring changes in body weight in ongoing clinical trials of FAAH inhibitors may clarify whether FAAH inhibition is a potential therapeutic strategy for treatment obesity. The gene discussed is FAAH; the disease is obesity due to melanocortin 4 receptor deficiency.